China’s Kidney Cancer Treatment Drugs Market Growth And Forecast Report : Radiant Insights,Inc
RadiantInsights.com has announced the addition of “China’s Kidney Cancer Treatment Drugs Market Trends, Growth And Forecast Report : Radiant Insights, Inc” Market Research Report to their Database.
San Francisco, United States – June 24, 2016 /MarketersMedia/ —
Kidney cancer, also known as renal cancer, targets cells in the kidney causing abnormal growth resulting in a tumor. There are mainly 2 types of renal cancer, namely transitional cell carcinoma and renal cell carcinoma.
China’s market for kidney cancer treatment drugs are estimated to grow at a robust rate over the forecast period (2018-2023). Factors such as smoking, obesity, and drinking alcohol are factors credited with cancer growth. The increasing population in China coupled with low presence of pharmaceutical companies provides growth opportunities for the market.
Browse Full Report With TOC @ http://www.radiantinsights.com/research/kidney-cancer-treatment-drugs-markets-in-china
The market is segmented according to the drugs available in the market. These drugs include Afinitor (Everolimus), Nexavar (Sorafebin), Sutent, Inlyta (Axitinib), Avastin (Bevaciazumab), Torisel (Temsirolimus), Proleukin (Aldesleukin/ Interlukin-2), and Votrient (Pazopanib). Although other treatments such as surgery, cryotherapy, and radiofrequency ablation are available, drugs are seen as a much economical option.
Sutent has shown better results when treating renal cancer. It is prescribed as the first line of defense against the disease. It is able to target multiple receptor tyrosine kinases (RTKs). Nexavar is likely to gain a large market share on account of the medicine being used to treat multiple diseases.
Opdivo is new drug manufactured by Bristol-Myers Squibb which received approval in 2015. It will be distributed worldwide, as it has been able to extend the survival rate of renal cancer patients by two years. Cabometyx, a similar drug launched by Exelixis was approved for the same reason. Both drugs will fight for market shares against Sutent, the current leader of the segment.
Request A Sample Copy Of This Report at: www.radiantinsights.com/research/kidney-cancer-treatment-drugs-markets-in-china/request-sample
The burgeoning economy of China is anticipated a huge market boost in the coming years. The geriatric populace at risk, low production cost of drugs, and consumer awareness regarding the medicine is expected to be a boon for the Chinese market.
Prominent players manufacturing kidney cancer treatment drugs in the Chinese market are F. Hoffmann-La Roche AG, Novartis International AG, Bayer Pharma AG, and GlaxoSmithKline plc. Companies involved in the market are investing in R&D to create drugs which can prolong the patient’s life. Mergers & acquisitions are another strategy adopted to sustain their market hold.
See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/healthcare
About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For more information, please visit http://www.radiantinsights.com/research/kidney-cancer-treatment-drugs-markets-in-china
Contact Info:
Name: Michelle Thoras
Email: sales@radiantinsights.com
Organization: Radiant Insights, Inc.
Address: 28 2nd Street, Suite 3036 San Francisco
Phone: 4153490054
Release ID: 120913
Copyright © 1999-2013 SproutNews.com
